Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Retrospective cohort study of selexipag in Chinese pulmonary arterial hypertension
ChiCTR2300067393Phase 4Recruiting
- Sponsor
- Qilu Hospital of Shandong University
- Start
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of selexipag in pulmonary arterial hypertension (PAH), sponsored by Qilu Hospital of Shandong University. Primary endpoint: French Pulmonary Hypertension Network non-invasive risk stratification. Started Sep 2022; status: recruiting.
02
Drugs
selexipag
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on ChiCTR2300067393.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300067393.